يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"Estrògens - Antagonistes - Ús terapèutic"', وقت الاستعلام: 0.81s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Bardia A Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Mayer I Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. AstraZeneca, Gaithersburg, MD, USA. Winer E Dana-Farber Cancer Institute, Boston, MA, USA. Yale Cancer Center, New Haven, CT, USA. Linden HM University of Washington, Seattle, WA, USA. Ma CX Washington University School of Medicine, St. Louis, MO, USA. Parker BA University of California San Diego Moores Cancer Center, San Diego, CA, USA. Bellet M Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Breast Cancer Research and Treatment;197; https://doi.org/10.1007/s10549-022-06797-9Test; Bardia A, Mayer I, Winer E, Linden HM, Ma CX, Parker BA, et al. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer. Breast Cancer Res Treat. 2023 Jan;197:319–31.; https://hdl.handle.net/11351/9315Test; 000885413200001

  2. 2

    المساهمون: Institut Català de la Salut, [Bardia A] Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. [Mayer I] Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. AstraZeneca, Gaithersburg, MD, USA. [Winer E] Dana-Farber Cancer Institute, Boston, MA, USA. Yale Cancer Center, New Haven, CT, USA. [Linden HM] University of Washington, Seattle, WA, USA. [Ma CX] Washington University School of Medicine, St. Louis, MO, USA. [Parker BA] University of California San Diego Moores Cancer Center, San Diego, CA, USA. [Bellet M] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf